Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: Efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy

Gynecologic Oncology

Volumn 71, Issue 1, 1998, Pages 113-115

  Markman, Maurie ^a   Kennedy, Alexander ^a   Webster, Kenneth ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; GRANISETRON; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; VOMITING;

EID: 0032191464     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5168     Document Type: Article

References (18)

1. Alberts D A, Green S, Hannigan E V, O'Toole R, Stock-Novack D, Anderson P, Surwit E A, Malvlya V K, Nahhas W A, Jolles C J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 10:1992;706-717.
2. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk M E, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 10:1992;718-726.
3. Calvert A H, Harland S J, Newell D R, Siddik Z H, Jones A C, McElwain T J, Raju S, Wiltshaw E, Smith I E, Baker J M, Peckham M M, Harrap K R. Early clinical studies withcis. Cancer Chemother Pharmacol. 9:1982;140-147.
4. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega J M. The natural course of emesis after carboplatin treatment. Acta Oncol. 29:1990;593-595.
5. Grunberg S M, Hesketh P J. Control of chemotherapy-induced emesis. N Engl J Med. 329:1993;1790-1796.
6. Perez E A. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol. 13:1995;1036-1043.
7. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone. Gynecol Oncol. 60:1996;435-437.
8. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. J Cancer Res Clin Oncol. 123:1997;224-226.
9. Hesketh P J, Harvey W H, Harker W G, Beck T M, Ryan T, Bricker L J, Kish J A, Murphy W K, Hainsworth J D, Haley B, Plagge P, Flack N E. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 12:1994;596-600.
10. Harvey V J, Evans B D, Mitchell P LR, Mak D, Neave L M, Langley G B, Dickson D SP. Reduction of carboplatin induced emesis by ondansetron. Br J Cancer. 63:1991;942-944.
11. Perez E A, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol. 16:1998;754-760.
12. Gralla R J, Navari R M, Hesketh P J, Popovic W, Strupp J, Nay J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 16:1998;1568-1573.
13. Rose W C, Schurig J E. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev. 12:1985;1-19.
14. Smith D B, Rustin G JS, Howells N, Lambert H E, McQuade B. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. Ann Oncol. 2:1991;607-608.
15. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinelli F, Bianco A R. Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy. Eur J Cancer. 29A:1993;651.
16. Sagar S M, Bayliss M A, Chong S L, Retsas S. Ondansetron: Further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy. Clin Oncol. 3:1991;183.
17. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol. 15:1997;3517.
18. Bookman M A, Kloth D D, Kover P E, Smolinski S, Ozols R F. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 8:1997;611-614.